Administration FUSFD. Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib) - U.S. Food & Drug Administration (FDA)
abgerufen am 19.05.2025.